RT-FIP
| Principal Investigator: | Peter Kozuch, MD |
| Time frame of study: | Ongoing |
| Location of Study: | Beth Israel Medical Center |
| Contact: | Continuum Cancer Research Program |
Summary:
New methods of management for patients with metastatic pancreatic cancer
use various combinations and sequences of gemcitabine, irinotecan, 5-fluorouracil,
and cisplatin. Combining the administration of these therapies with EBRT
(electron beam radiation therapy) may improve control of locoregional
disease as well as subclinical metastases (spread of the cancer that stays
below the surface of clinical detection).
Incorporation of irinotecan, a drug with demonstrated single agent and
possible additive activity with chemotherapy and radiosensitizing properties
will be explored.
Eligibility and Treatment Plan:
Patients, 18 years and older, with pathologically confirmed, adenocarcinoma
of the pancreas; patients must have unresectable disease.
After entry into the study, all eligible subjects will receive chemotherapy (Step 1), chemotherapy + radiation (Step 2), and then chemotherapy (Step 3):
• Step 1: Gemcitabine + Irinotecan + Leucovorin + 5-FU + Cisplatin
• Step 2: Radiation therapy + Irinotecan + 5-FU + Cisplatin
• Step 3: Gemcitabine + Irinotecan + Leucovorin + 5-FU + Cisplatin
Benefits and/or Compensation:
Participation in this study is voluntary and no compensation for participation
will be given. You will not be reimbursed for medical care other than
what your insurance carrier may provide. The possible benefits of this
research program are greater shrinkage and control of your tumor and prolongation
of your life but this is not guaranteed. The information obtained from
this study will be used scientifically and may be helpful to others.
Copyright © 2008